Figure 1. Treatment response to evofosfamide and fractionated irradiation in vivo.

Tumor growth delay of A549-derived (A) and UT-SCC-14-derived (B) tumor xenografts in response to different treatment schedules of the combined treatment modality with evofosfamide (50 mg/kg, Q3Dx5) and fractionated irradiation (3×2 Gy). Control mice were treated i.p. with saline. Neoadjuvant (left panel), concomitant (middle panel), and adjuvant (right panel) regimens are shown. Neoadjuvant (left panel), with evofosfamide given on days 1-12 followed by fractionated irradiation; concomitant (middle panel), with evofosfamide given on days 1-12 and IR on days 5-7; adjuvant (right panel), IR given on days 0-2 (fractionated) followed by treatment with evofosfamide. 7-8 mice per treatment groups were used. Error bars represent SEM. (C) Kaplan-Meier curves for A549-derived tumors reaching 600mm³ tumor volume.